The law firm of Kessler Topaz Meltzer & Check, LLP has announced an investigation into potential violations of federal securities laws concerning uniQure N.V. (NASDAQ: QURE), following a significant drop in the company’s stock price. On November 3, 2025, uniQure revealed that the U.S. Food and Drug Administration (FDA) had informed the company that the data supporting its investigational gene therapy, AMT-130, for treating Huntington’s disease, was insufficient for a Biologics License Application (BLA) submission.
In the announcement, uniQure indicated that the FDA no longer considers the data from its Phase I/II studies adequate to support the BLA submission for AMT-130. As a result, the timeline for this application has become uncertain. Following the news, uniQure’s stock plummeted by over 50%, closing at $34.29 on November 3, down from $67.69 on October 31, 2025.
Kessler Topaz is reaching out to investors who have experienced significant losses related to uniQure’s stock. The firm invites affected investors to participate in its investigation to explore potential recovery options. Interested individuals can fill out an online form provided by Kessler Topaz or contact the firm directly.
The firm is known for its work in prosecuting class actions in both state and federal courts across the United States. Kessler Topaz has a track record of tackling securities fraud, breaches of fiduciary duties, and various violations of state and federal law. Over the years, the firm has been instrumental in corporate governance reform and has successfully recovered billions for investors both domestically and internationally.
For more information regarding this investigation or to inquire about potential claims, investors can contact Jonathan Naji, Esq., at Kessler Topaz Meltzer & Check, LLP, located in Radnor, Pennsylvania. The firm emphasizes that past results do not guarantee future outcomes, and the information provided may be considered attorney advertising in certain jurisdictions.
Investors are encouraged to act swiftly as the situation develops, given the significant financial implications stemming from the recent FDA notification.
